Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 EUR | -2.31% | -6.94% | -69.70% |
28/06 | AB Science: negative CHMP opinion for masitinib in ALS | CF |
03/06 | AB Science: share price falls on resumption of trading | CF |
Business Summary
Number of employees: 54
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Protein Kinase Inhibitors
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +1.25% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +1.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 11/01/11 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01/02/01 |
Chief Tech/Sci/R&D Officer | - | 01/18/01 | |
Alexis Bernard
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 11/01/11 |
Patrick Moussy
BRD | Director/Board Member | - | 11/01/11 |
Director/Board Member | 62 | 27/21/27 | |
Director/Board Member | 66 | 27/21/27 | |
Director/Board Member | - | 27/21/27 | |
Renaud Sassi
BRD | Director/Board Member | - | 27/21/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 51,111,703 | 32,744,501 ( 64.06 %) | 0 | 64.06 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.39% | 72.09B | |
+15.93% | 9.05B | |
+17.59% | 4.39B | |
-22.81% | 4.4B | |
+25.93% | 3.94B | |
+4.64% | 2.1B | |
+9.09% | 1.97B | |
-36.86% | 1.87B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- AB Stock
- A8D Stock
- Company AB Science